Siemens Healthineers is a global medical technology company which was spun out of Siemens AG in 2017. Through four business segments, it specialises in the provision of diagnostic imaging, diagnostics, radiation oncology equipment and equipment for minimally invasive surgeries (MIS). All four segments help contribute towards either an improved quality of life and/or extending life expectancy for patients.
Objective
For Siemens Healthineers to publish data that helps to strengthen investors’ understanding of the positive impacts enabled through its products and services.
Background
We continually seek to further strengthen our understanding of the positive impact associated with the products and services sold by our investee companies. Additional insights allow us to build a stronger investment case and ‘impact story’ for each of our stocks. WHEB encourages investee companies to improve how they report on the positive sustainability impacts of their products and services. This helps other investors recognise these companies as having a strong impact, making it easier for them to direct capital toward these businesses.
Actions
The Investor Relations representative for Siemens Healthineers visited our offices. This gave us the opportunity to ask him for further information and data with regards to the positive impact of the company's Varian segment on patient outcomes.
Progress/Outcomes
M2
Siemen’s Healthineers shared information regarding Varian's latest innovation, HyperSight. This technology offers significantly higher resolution imaging and drastically reduces image acquisition time from 60 seconds to just 6 seconds. This enables better visualization and faster workflow. Importantly, HyperSight allows real-time adaptation of treatment if the tumour or surrounding organs have shifted, avoiding delays and ensuring more effective, personalized therapy. This innovation improves clinical outcomes by offering superior accuracy and flexibility in treatment, benefiting patient care.